US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...
Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing ...
The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback